146 related articles for article (PubMed ID: 1380888)
21. Detection of circulating breast cancer cells in peripheral blood by a two-marker reverse transcriptase-polymerase chain reaction assay.
Fabisiewicz A; Kulik J; Kober P; Brewczyńska E; Pieńkowski T; Siedlecki JA
Acta Biochim Pol; 2004; 51(3):747-55. PubMed ID: 15448736
[TBL] [Abstract][Full Text] [Related]
22. Useful markers for detecting minimal residual disease in cases of neuroblastoma.
Ootsuka S; Asami S; Sasaki T; Yoshida Y; Nemoto N; Shichino H; Chin M; Mugishima H; Suzuki T
Biol Pharm Bull; 2008 Jun; 31(6):1071-4. PubMed ID: 18520032
[TBL] [Abstract][Full Text] [Related]
23. Reverse transcriptase polymerase chain reaction for prostate specific antigen in the management of prostate cancer.
Gomella LG; Raj GV; Moreno JG
J Urol; 1997 Aug; 158(2):326-37. PubMed ID: 9224297
[TBL] [Abstract][Full Text] [Related]
24. Circulating neuroblastoma cells detected by reverse transcriptase polymerase chain reaction for tyrosine hydroxylase mRNA are an independent poor prognostic indicator in stage 4 neuroblastoma in children over 1 year.
Burchill SA; Lewis IJ; Abrams KR; Riley R; Imeson J; Pearson AD; Pinkerton R; Selby P
J Clin Oncol; 2001 Mar; 19(6):1795-801. PubMed ID: 11251011
[TBL] [Abstract][Full Text] [Related]
25. Comparison of immunocytochemistry, real-time quantitative RT-PCR and flow cytometry for detection of minimal residual disease in neuroblastoma.
Ifversen MR; Kågedal B; Christensen LD; Rechnitzer C; Petersen BL; Heilmann C
Int J Oncol; 2005 Jul; 27(1):121-9. PubMed ID: 15942651
[TBL] [Abstract][Full Text] [Related]
26. Quantitation of marrow disease in neuroblastoma by real-time reverse transcription-PCR.
Cheung IY; Cheung NK
Clin Cancer Res; 2001 Jun; 7(6):1698-705. PubMed ID: 11410509
[TBL] [Abstract][Full Text] [Related]
27. Real-time RT-PCR of tyrosine hydroxylase to detect bone marrow involvement in advanced neuroblastoma.
Pession A; Libri V; Sartini R; Conforti R; Magrini E; Bernardi L; Fronza R; Olivotto E; Prete A; Tonelli R; Paolucci G
Oncol Rep; 2003; 10(2):357-62. PubMed ID: 12579272
[TBL] [Abstract][Full Text] [Related]
28. Detection of neuroblastoma cells during clinical follow up: advanced flow cytometry and rt-PCR for tyrosine hydroxylase using both conventional and real-time PCR.
Esser R; Glienke W; Bochennek K; Erben S; Quaiser A; Pieper C; Eggert A; Schramm A; Astrahantseff K; Hansmann ML; Schwabe D; Klingebiel T; Koehl U
Klin Padiatr; 2011 Nov; 223(6):326-31. PubMed ID: 22095188
[TBL] [Abstract][Full Text] [Related]
29. Sensitive detection of rare cancer cells in sputum and peripheral blood samples of patients with lung cancer by preproGRP-specific RT-PCR.
Lacroix J; Becker HD; Woerner SM; Rittgen W; Drings P; von Knebel Doeberitz M
Int J Cancer; 2001 Apr; 92(1):1-8. PubMed ID: 11279599
[TBL] [Abstract][Full Text] [Related]
30. Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force.
Beiske K; Burchill SA; Cheung IY; Hiyama E; Seeger RC; Cohn SL; Pearson AD; Matthay KK;
Br J Cancer; 2009 May; 100(10):1627-37. PubMed ID: 19401690
[TBL] [Abstract][Full Text] [Related]
31. Significance of molecular quantification of minimal residual disease in metastatic neuroblastoma.
Tchirkov A; Paillard C; Halle P; Bernard F; Bordigoni P; Vago P; Deméocq F; Kanold J
J Hematother Stem Cell Res; 2003 Aug; 12(4):435-42. PubMed ID: 12965080
[TBL] [Abstract][Full Text] [Related]
32. Sensitive detection of small cell lung carcinoma cells by reverse transcriptase-polymerase chain reaction for prepro-gastrin-releasing peptide mRNA.
Saito T; Kobayashi M; Harada R; Uemura Y; Taguchi H
Cancer; 2003 May; 97(10):2504-11. PubMed ID: 12733150
[TBL] [Abstract][Full Text] [Related]
33. Detection of the PGP9.5 and tyrosine hydroxylase mRNAs for minimal residual neuroblastoma cells in bone marrow and peripheral blood.
Yanagisawa TY; Sasahara Y; Fujie H; Ohashi Y; Minegishi M; Itano M; Morita S; Tsuchiya S; Hayashi Y; Ohi R; Konno T
Tohoku J Exp Med; 1998 Mar; 184(3):229-40. PubMed ID: 9591338
[TBL] [Abstract][Full Text] [Related]
34. Potential application of ELAVL4 real-time quantitative reverse transcription-PCR for detection of disseminated neuroblastoma cells.
Swerts K; De Moerloose B; Dhooge C; Vandesompele J; Hoyoux C; Beiske K; Benoit Y; Laureys G; Philippé J
Clin Chem; 2006 Mar; 52(3):438-45. PubMed ID: 16384890
[TBL] [Abstract][Full Text] [Related]
35. Detection of breast cancer micrometastases in axillary lymph nodes by means of reverse transcriptase-polymerase chain reaction. Comparison between MUC1 mRNA and keratin 19 mRNA amplification.
Noguchi S; Aihara T; Motomura K; Inaji H; Imaoka S; Koyama H
Am J Pathol; 1996 Feb; 148(2):649-56. PubMed ID: 8579127
[TBL] [Abstract][Full Text] [Related]
36. Detecting minimal residual disease in neuroblastoma patients-the present state of the art.
Beiske K; Ambros PF; Burchill SA; Cheung IY; Swerts K
Cancer Lett; 2005 Oct; 228(1-2):229-40. PubMed ID: 15951104
[TBL] [Abstract][Full Text] [Related]
37. [Detection of disseminated carcinoma cells in bone marrow and peripheral blood in primary breast cancer with RT/PCR of parathyroid hormone-related protein (PTHrP)].
Liersch T; Gatzemeier W; Scharnberg P; Jürgens B; Wörmann B; Becker H; Rauschecker HF; Hiddemann W; Wulf GG
Langenbecks Arch Chir Suppl Kongressbd; 1998; 115(Suppl I):277-80. PubMed ID: 14518259
[TBL] [Abstract][Full Text] [Related]
38. Detection of circulating prostate specific antigen expressing prostatic cells in the bone marrow of radical prostatectomy patients by sensitive reverse transcriptase polymerase chain reaction.
Gao CL; Dean RC; Pinto A; Mooneyhan R; Connelly RR; McLeod DG; Srivastava S; Moul JW
J Urol; 1999 Apr; 161(4):1070-6. PubMed ID: 10081840
[TBL] [Abstract][Full Text] [Related]
39. Comparison of molecular cytokeratin 19 reverse transcriptase polymerase chain reaction (CK19 RT-PCR) and immunocytochemical detection of micrometastatic breast cancer cells in hematopoietic harvests.
Traystman MD; Cochran GT; Hake SJ; Kuszynski CA; Mann SL; Murphy BJ; Pirruccello SJ; Zuvanich E; Sharp JG
J Hematother; 1997 Dec; 6(6):551-61. PubMed ID: 9483190
[TBL] [Abstract][Full Text] [Related]
40. PHOX2B is a novel and specific marker for minimal residual disease testing in neuroblastoma.
Stutterheim J; Gerritsen A; Zappeij-Kannegieter L; Kleijn I; Dee R; Hooft L; van Noesel MM; Bierings M; Berthold F; Versteeg R; Caron HN; van der Schoot CE; Tytgat GA
J Clin Oncol; 2008 Nov; 26(33):5443-9. PubMed ID: 18838715
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]